# OnCo record intuitt-nf2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/intuitt-nf2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "intuitt-nf2", "NCT04374305" ;
  schema:name "INTUITT-NF2"@en ;
  schema:description "INTUITT-NF2 is a rolling trial for people with the inherited condition NF2, who grow many benign tumours of the nerves and brain lining; its first drug, brigatinib, shrank a share of tumours, slowed the growth of all types and improved hearing in a third of affected ears, which is the evidence behind offering it for these tumours."@en ;
  schema:url <https://onco.cc/trials/intuitt-nf2/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04374305> ;
  onco:status "recruiting" ;
  onco:tag "soc-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/vestibular-schwannoma/>, <https://onco.cc/cancers/meningioma/>, <https://onco.cc/cancers/brain-tumours/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/brigatinib/>, <https://onco.cc/drugs/neratinib/>, <https://onco.cc/drugs/retifanlimab/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:companies <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/incyte/> ;
  onco:institutions <https://onco.cc/institutions/mgh/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-intuitt-nf2-brigatinib-plotkin-nejm-2024/> .